Manuela Borges Sangoi1, José Antonio M de Carvalho2, Etiane Tatsch3, Bruna S Hausen3, Yãnaí S Bollick4, Sílvia W K Londero5, Thiago Duarte6, Rogério Scolari7, Marta M M F Duarte8, Melissa O Premaor9, Fabio V Comim9, Maria B Moretto10, Rafael N Moresco11. 1. Laboratory of Clinical Biochemistry, Department of Clinical and Toxicological Analysis, Federal University of Santa Maria, Santa Maria, RS, Brazil; Department of Health Sciences, Integrated Regional University of High Uruguay and Missions, Santiago, RS, Brazil; Pharmaceutical Sciences Postgraduate Program, Federal University of Santa Maria, Santa Maria, RS, Brazil. 2. Laboratory of Clinical Biochemistry, Department of Clinical and Toxicological Analysis, Federal University of Santa Maria, Santa Maria, RS, Brazil; University Hospital, Federal University of Santa Maria, Santa Maria, RS, Brazil. 3. Laboratory of Clinical Biochemistry, Department of Clinical and Toxicological Analysis, Federal University of Santa Maria, Santa Maria, RS, Brazil; Pharmaceutical Sciences Postgraduate Program, Federal University of Santa Maria, Santa Maria, RS, Brazil. 4. Laboratory of Clinical Biochemistry, Department of Clinical and Toxicological Analysis, Federal University of Santa Maria, Santa Maria, RS, Brazil. 5. University Hospital, Federal University of Santa Maria, Santa Maria, RS, Brazil. 6. Pharmacology Postgraduate Program, Federal University of Santa Maria, Santa Maria, RS, Brazil. 7. Clinical Analysis Laboratory, Labimed, Santa Maria, RS, Brazil. 8. Pharmacology Postgraduate Program, Federal University of Santa Maria, Santa Maria, RS, Brazil; Clinical Analysis Laboratory, Labimed, Santa Maria, RS, Brazil; Department of Health Sciences, Lutheran University of Brazil, Santa Maria, RS, Brazil. 9. Pharmacology Postgraduate Program, Federal University of Santa Maria, Santa Maria, RS, Brazil; Department of Clinical Medicine, Federal University of Santa Maria, Santa Maria, RS, Brazil. 10. Pharmaceutical Sciences Postgraduate Program, Federal University of Santa Maria, Santa Maria, RS, Brazil; Pharmacology Postgraduate Program, Federal University of Santa Maria, Santa Maria, RS, Brazil. 11. Laboratory of Clinical Biochemistry, Department of Clinical and Toxicological Analysis, Federal University of Santa Maria, Santa Maria, RS, Brazil; Pharmaceutical Sciences Postgraduate Program, Federal University of Santa Maria, Santa Maria, RS, Brazil; Pharmacology Postgraduate Program, Federal University of Santa Maria, Santa Maria, RS, Brazil. Electronic address: rnmoresco@ufsm.br.
Abstract
BACKGROUND: The aim of this study was to investigate whether urinary levels of interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) are altered in normoalbuminuric patients with type 2 diabetes mellitus (T2DM), and whether these cytokines are able to identify diabetic kidney disease (DKD) among these patients. METHODS: This study included 125 T2DM patients classified into 3 groups according to urinary albumin/creatinine ratio (uACR): uACR <10mg/g creatinine, uACR 10-30mg/g creatinine and uACR >30mg/g creatinine. Urinary inflammatory cytokines were measured. RESULTS: The urinary IL-6 concentrations increased from uACR <10 (97.2±26.4pg/ml) to uACR 10-30 (113.6±28.0pg/ml) and to uACR >30mg/g creatinine (163.5±25.6pg/ml) (P<0.05 and P<0.001, respectively) patients. The urinary IL-10 concentrations decreased in these uACR ranges [100.0 (58.0-141.0) pg/ml vs. 62.0 (54.5-71.5) pg/ml vs. 42.0 (32.0-48.0) pg/ml] (P<0.05 and P<0.001, respectively). All urinary cytokines demonstrated good ability to identify DKD (areas under curves >0.9). CONCLUSIONS: Urinary inflammatory cytokines, especially IL-6 and IL-10, may assist in the identification of DKD in T2DM patients, even in the absence of micro- and macroalbuminuria.
BACKGROUND: The aim of this study was to investigate whether urinary levels of interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) are altered in normoalbuminuric patients with type 2 diabetes mellitus (T2DM), and whether these cytokines are able to identify diabetic kidney disease (DKD) among these patients. METHODS: This study included 125 T2DM patients classified into 3 groups according to urinary albumin/creatinine ratio (uACR): uACR <10mg/g creatinine, uACR 10-30mg/g creatinine and uACR >30mg/g creatinine. Urinary inflammatory cytokines were measured. RESULTS: The urinary IL-6 concentrations increased from uACR <10 (97.2±26.4pg/ml) to uACR 10-30 (113.6±28.0pg/ml) and to uACR >30mg/g creatinine (163.5±25.6pg/ml) (P<0.05 and P<0.001, respectively) patients. The urinary IL-10 concentrations decreased in these uACR ranges [100.0 (58.0-141.0) pg/ml vs. 62.0 (54.5-71.5) pg/ml vs. 42.0 (32.0-48.0) pg/ml] (P<0.05 and P<0.001, respectively). All urinary cytokines demonstrated good ability to identify DKD (areas under curves >0.9). CONCLUSIONS: Urinary inflammatory cytokines, especially IL-6 and IL-10, may assist in the identification of DKD in T2DM patients, even in the absence of micro- and macroalbuminuria.
Authors: E G Dorsey-Treviño; J G González-González; N Alvarez-Villalobos; V González-Nava; B M Contreras-Garza; A Díaz González-Colmenero; G Rodríguez-Tamez; F J Barrera-Flores; A M Farrell; V M Montori; R Rodriguez-Gutierrez Journal: J Endocrinol Invest Date: 2019-09-05 Impact factor: 4.256
Authors: Naiara S Guarda; Yãnaí S Bollick; José Antonio M de Carvalho; Melissa O Premaor; Fabio V Comim; Rafael N Moresco Journal: Dis Markers Date: 2019-04-11 Impact factor: 3.434
Authors: Irena Markova; Martina Hüttl; Olena Oliyarnyk; Tereza Kacerova; Martin Haluzik; Petr Kacer; Ondrej Seda; Hana Malinska Journal: Nutr Metab (Lond) Date: 2019-08-01 Impact factor: 4.169